Regeneron
 |
|
| Type | Public (NASDAQ:REGN)(virt-x:REGN) |
|---|---|
| Industry | Pharmaceuticals; Biotech |
| Founded | 1988 |
| Headquarters | Tarrytown, New York, US (Headquarters) |
| Key people | Leonard Schleifer (CEO), |
| Website | www.regeneron.com |
Regeneron is a biotechnology company headquartered in Tarrytown, in New York, US The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities (thus the name), it branched out into the study of both cytokine and tyrosine kinase receptors.
Regeneron has two products in development based on aflibercept, a VEGF inhibitor, and rilonacept, an interleukin-1 blocker. VEGF is a protein that normally stimulates the growth of blood vessels, and interleukin-1 is a protein that is normally involved in inflammation.
Contents |
[edit] Marketed products
EYLEA™ (aflibercept injection): Approved by the U.S. Food and Drug Administration (FDA) in November 2011
ARCALYST® (rilonacept) Injection for Subcutaneous Use: Approved by the FDA in February 2008
[edit] Products in development
Inflammation:
-Rilonacept, a trap for the interleukin-1 (IL-1) cytokine, is in development for the prevention of gout flares in patients who are initiating uric acid lowering therapy.
-Sarilumab (REGN88) a fully human monoclonal antibody to the interleukin-6 receptor (IL-6R), is in development for the treatment of rheumatoid arthritis.
-REGN668, a fully human monoclonal antibody to the interleukin-4 (IL-4) and interleukin-13 (IL-13) receptors, is in development for certain allergic and immune conditions.
-REGN846, a fully human monoclonal antibody to an undisclosed target, is in development in atopic dermatitis.
Metabolism:
-REGN727, a fully human monoclonal antibody to Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), is in development for LDL cholesterol reduction in patients with hyperlipidemia.
Oncology: The following drug candidates are in various stages of development to disrupt tumor growth in patients with cancer:
-Aflibercept concentrate (VEGF-Trap), a Trap for the blood vessel growth factors VEGF-A, VEGF-B, and PIGF.
-REGN421, a fully human monoclonal antibody to Delta-like ligand 4 (DLL4)
-REGN910, a fully human monoclonal antibody to Angiopoietin-2 (Ang-2)
Opthalmology:
-Aflibercept injection, a Trap to VEGF-A and PIGF, is in development for the treatment of eye disease by local administration.
Pain:
-REGN475, a fully human monoclonal antibody to Nerve Growth Factor (NGF), is currently on clinical hold.
Another fully human monoclonal antibody, REGN728, is currently in development to an undisclosed target.
The safety and efficacy of these drug candidates have not been evaluated by any regulatory authorities for the indications described in this section.
[edit] Technology platforms
Trap Fusion Proteins: Regeneron’s novel and patented Trap technology creates high-affinity product candidates for many types of signaling molecules, including growth factors and cytokines. The Trap technology involves fusing two distinct fully human receptor components and a fully human immunoglobulin-G constant region.
Fully Human Monoclonal Antibodies: Regeneron has developed a suite (VelociSuite) of patented technologies, including VelocImmune and VelociMab, that allow Regeneron scientists to determine the best targets for therapeutic intervention and rapidly generate high-quality, fully human antibodies drug candidates addressing these targets.
